An increasing number of studies have confirmed PAX1 methylation as a promising biomarker for cervical cancer based on its ability to discriminate between high‐grade cervical lesions and normal tissues, resulting in a reduced necessity for colposcopy referral and biopsy (9, 10, 34). This evidence concerns the gene PAX1 and cervical carcinoma.